Cited by 446Cannabis and Cannabinoid ResearchNeuroscience and Neuropharmacology ResearchMedicinal Plant Extracts Effects

Cannabidiol, neuroprotection and neuropsychiatric disorders

Campos, Alline C., Fogaça, Manoela V., Sonego, Andreza B., Guimarães, Francisco S.·2016·Pharmacological Research

Abstract

Cannabidiol (CBD) is a non-psychotomimetic phytocannabinoid derived from Cannabis sativa. It has possible therapeutic effects over a broad range of neuropsychiatric disorders. CBD attenuates brain damage associated with neurodegenerative and/or ischemic conditions. It also has positive effects on attenuating psychotic-, anxiety- and depressive-like behaviors. Moreover, CBD affects synaptic plasticity and facilitates neurogenesis. The mechanisms of these effects are still not entirely clear but seem to involve multiple pharmacological targets. In the present review, we summarized the main biochemical and molecular mechanisms that have been associated with the therapeutic effects of CBD, focusing on their relevance to brain function, neuroprotection and neuropsychiatric disorders.

Integrity signals

Registry

Crossref · 10.1016/j.phrs.2016.01.033

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Campos, A. C., Fogaça, M. V., Sonego, A. B., & Guimarães, F. S.
Affiliations
Universidade de São Paulo (BR)
Corresponding author
Campos, Alline C.
Venue
Pharmacological Research
Publisher
Elsevier BV
Published
2016-10
Volume
112
Pages
119-127
ISSN
1043-6618 (ISSN-L)
OpenAlex
W2283995152
Cited by
446
References
18
Citations by year
2026: 32 · 2025: 30 · 2024: 44 · 2023: 85 · 2022: 43 · 2021: 74 · 2020: 43 · 2019: 36 · 2018: 29 · 2017: 23 · 2016: 7
FWCI
3.42
Type
journal article
Language
en
Open access
closed
Locations
  • Pharmacological Research (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology › Cannabis and Cannabinoid Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
  • Health Sciences › Medicine › Complementary and alternative medicine › Medicinal Plant Extracts Effects
Keywords
cannabidiol, neuroprotection, neuropsychiatric disorders, neurodegeneration, cerebral ischemia, psychosis, anxiety, depression, synaptic plasticity, neurogenesis, phytocannabinoids, Cannabis sativa, molecular mechanisms
MeSH terms
Neuroprotection, Animals, Mental Disorders, Brain Diseases, Cannabidiol, Clinical Trials as Topic, Humans, Neuroprotective Agents, Drug Discovery

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review